

United Health Products, Inc.  
Form 8-K  
March 06, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report, (Date of earliest event reported): **March 6, 2017**

**UNITED HEALTH PRODUCTS,  
INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**814-00717**  
(Commission  
File Number)

**84-1517723**  
(I.R.S. Employer  
Identification No.)

**10624 S. Eastern Ave., Ste. A209**

**Henderson, NV 89052**

(Address of principal executive offices, zip code)

**(877) 358-3444**

Edgar Filing: United Health Products, Inc. - Form 8-K

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

United Health Products Inc. (UEEC) has filed a FDA (Food and Drug Administration) 510K Class II Application for expanded usage of its patented HemoStyp® products. The application will include expanded usage into general surgeries and internal procedures. HemoStyp® Dressings are made from regenerated cotton cellulose, treated with natural chemicals to become water soluble. When contacting blood and exudates, the cellulose expands into a clear gel, thereby adhering and creating pressure to seal the wound. HemoStyp® products are 100% cellulose and all natural. United Health Products Inc. anticipates a response from the FDA within 90 days.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**United Health Products, Inc.**

Dated: March 6, 2017

By: */s/ Douglas Beplate*  
Douglas Beplate, Chief Executive  
Officer